William Blair analyst Andy Hsieh initiated coverage of Elevation Oncology (ELEV) with an Outperform rating.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELEV:
- Elevation Oncology nominates EO-1022 as its HER3 ADC development candidate
- Elevation Oncology enters licensing agreement with Synaffix B.V.
- Elevation Oncology presents positive Phase 1 results of EO-3021 combination
- Elevation Oncology’s Q3 2024 Highlights and Financial Report
- Elevation Oncology reports Q3 EPS (22c), consensus (20c)